raav2.rep1

Gene therapyexperimental

Clinical trial activity

3 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2011 (NCT01461213)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • raav2.rep1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02671539Phase 2Jan 1, 2016STZ eyetrial, University of Tuebingen
NCT02077361Phase 1/Phase 2 (Phase 2)Apr 1, 2015Alberta Innovates Health Solutions, Canada Foundation for Innovation, Canadian Institutes of Health Research (CIHR), Choroideremia Research Foundation Canada, Foundation Fighting Blindness, University of Alberta, University of London, University of Oxford
NCT01461213Phase 1/Phase 2 (Phase 2)Oct 1, 2011Moorgreen Hospital, Southampton, University of London, University of Manchester, University of Oxford
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LondonAcademic/Hospital2012011
University of OxfordAcademic/Hospital2112011
Alberta Innovates Health SolutionsAcademic/Hospital1012015
Canada Foundation for InnovationAcademic/Hospital1012015
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012015
Choroideremia Research Foundation CanadaAcademic/Hospital1012015
Foundation Fighting BlindnessAcademic/Hospital1012015
Moorgreen Hospital, SouthamptonAcademic/Hospital1012011
STZ eyetrialAcademic/Hospital1112016
University of AlbertaAcademic/Hospital1112015
University of ManchesterAcademic/Hospital1012011
University of TuebingenAcademic/Hospital1012016
12 organizations
Page 1 / 1